{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T20:52:41Z","timestamp":1782679961842,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.annder.2020.07.013","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T08:43:58Z","timestamp":1600159438000},"page":"833-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hypodermite sous inhibiteur de BRAF et\/ou inhibiteur de MEK\u00a0: revue de la litt\u00e9rature \u00e0 partir d\u2019une nouvelle observation"],"prefix":"10.1016","volume":"147","author":[{"given":"M.","family":"Piroth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fr\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Eug\u00e8ne-Lamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2020.07.013_bib0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","article-title":"Cutaneous adverse effects of targeted therapies","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0155","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ad.2016.05.019","article-title":"Cutaneous adverse events of new anti-melanoma therapies: classification and management","volume":"108","author":"Hwang","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.annder.2020.07.013_bib0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0165","doi-asserted-by":"crossref","first-page":"CRA8503","DOI":"10.1200\/jco.2011.29.18_suppl.cra8503","article-title":"Phase I\/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1\/2\u00a0inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436(GSK436)","volume":"29","author":"Infante","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2020.07.013_bib0170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/DAD.0000000000000023","article-title":"Panniculitis in patients treated with BRAF inhibitors: a case series","volume":"36","author":"Choy","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2020.07.013_bib0175","doi-asserted-by":"crossref","first-page":"e0214884","DOI":"10.1371\/journal.pone.0214884","article-title":"Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: potential predictive role of treatment efficacy","volume":"14","author":"Consoli","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.annder.2020.07.013_bib0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/pde.12316","article-title":"Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma","volume":"32","author":"West","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0185","first-page":"384","article-title":"Delayed-onset vemurafenib-induced panniculitis","volume":"3","author":"Vance","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00000372-198804000-00006","article-title":"Melanophagic dermatitis and panniculitis. A condition revealing an occult metastatic malignant melanoma","volume":"10","author":"Pi\u00e9rard","year":"1988","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2020.07.013_bib0195","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0190-9622(98)70370-6","article-title":"Melanoma-in-transit presenting as panniculitis","volume":"39","author":"Cotton","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0200","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1097\/RLU.0000000000001027","article-title":"BRAF inhibitor-induced panniculitis: appearance on 18F-FDG PET\/CT","volume":"41","author":"Broski","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.annder.2020.07.013_bib0205","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/jdv.12397","article-title":"BRAF inhibitors-induced panniculitis: a cutaneous side effect mimicking subcutaneous melanoma metastasis","volume":"29","author":"Chaminade","year":"2015","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0210","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favourable tumour microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2020.07.013_bib0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2018.06.030","article-title":"Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600\u2013mutant metastatic melanoma","volume":"101","author":"Ben-Betzalel","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2020.07.013_bib0220","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1111\/ijd.13566","article-title":"Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management","volume":"56","author":"Ueno","year":"2017","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0225","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1684\/ejd.2012.1915","article-title":"Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma","volume":"23","author":"Degen","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0230","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000461571","article-title":"Panniculitis associated with MEK inhibitor therapy: an uncommon adverse effect","volume":"9","author":"Negulescu","year":"2017","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/CMR.0b013e3283570792","article-title":"Vemurafenib-induced neutrophilic panniculitis","volume":"22","author":"Monfort","year":"2012","journal-title":"Melanoma Res"},{"key":"10.1016\/j.annder.2020.07.013_bib0240","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.13039","article-title":"Erythema nodosum-like lesions during BRAF inhibitor therapy: report on 16\u00a0new cases and review of the literature","volume":"29","author":"M\u00f6ssner","year":"2015","journal-title":"J Eur Acad Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0245","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.jaad.2012.05.019","article-title":"Vasculitis and panniculitis associated with vemurafenib","volume":"67","author":"Novoa","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0250","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D370X41670","article-title":"Vemurafenib-associated neutrophilic panniculitis: an emergent adverse effect of variable severity","volume":"19","author":"Maldonado-Seral","year":"2013","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2020.07.013_bib0255","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1200\/JCO.2012.45.8307","article-title":"Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib","volume":"31","author":"Sinha","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2020.07.013_bib0260","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/cup.12149","article-title":"Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib: neutrophilic panniculitis after vemurafenib","volume":"40","author":"Kim","year":"2013","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2020.07.013_bib0265","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1684\/ejd.2013.1991","article-title":"Vemurafenib-induced panniculitis","volume":"23","author":"Villani","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0270","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2014.2512","article-title":"Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor","volume":"25","author":"Galliker","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2020.07.013_bib0275","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1097\/DAD.0000000000000230","article-title":"Panniculitis with necrotizing granulomata in a patient on BRAF inhibitor (Dabrafenib) therapy for metastatic melanoma","volume":"37","author":"Ramani","year":"2015","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2020.07.013_bib0280","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1097\/DAD.0000000000000528","article-title":"Vemurafenib-induced neutrophilic panniculitis: a new case and review of the literature","volume":"38","author":"V\u00e1zquez-Osorio","year":"2016","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.annder.2020.07.013_bib0285","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/cup.12857","article-title":"BRAFi-associated panniculitis \u2013 an emerging side effect with a variable histological picture: report of two cases and review of the literature","volume":"44","author":"Ferreira","year":"2017","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2020.07.013_bib0145","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid-like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou","year":"2018","journal-title":"Melanoma Res"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820303173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963820303173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:10:04Z","timestamp":1758971404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963820303173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0151963820303173"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2020.07.013","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypodermite sous inhibiteur de BRAF et\/ou inhibiteur de MEK\u00a0: revue de la litt\u00e9rature \u00e0 partir d\u2019une nouvelle observation","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2020.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}